Security
VivoSim Labs, Inc. Common Stock · VIVS
VIVSNASDAQCommon stockCurrentCIK 1497253Updated Oct 19, 2026
Name history
ORGANOVO HOLDINGS, INC. · through Apr 23, 2025REAL ESTATE RESTORATION & RENTAL, INC. · through Oct 31, 2011
VIVS price & chart
Loading TradingView…
NASDAQ:VIVS on TradingView ↗About the company
We are a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. We offer partners liver and intestinal toxicology insights using our new approach methodologies (“NAM”) models. We anticipate accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA”) announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. We also expect to offer bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of these complex human tissue models.
In the news
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor ↗
Seeking Alpha
VivoSim expects FY27 revenue growth of over 500%, receives $5M milestone payment from Eli Lilly ↗
VivoSim announces pricing of up to $4M public offering ↗
SEC disclosures
VivoSim Labs, INC. files 8-K: Material Event ↗
Recent filings
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
4 filing
ARS filing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01, 9.01
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2027 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 3,844,000Source | — | 6,754,000Source | — | 3,847,000Source | — | 9,470,000Source | — | 7,386,000Source | 14,650,000Source | 6,349,000Source | 20,313,000Source |
| Property, Plant and Equipment, NetUSD | 479,000Source | — | 545,000Source | — | 189,000Source | — | 601,000Source | — | 206,000Source | 419,000Source | 669,000Source | 902,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,161,000Source | 5,295,000Source | 3,174,000Source | 7,617,000Source | 1,670,000Source | 9,055,000Source | 6,187,000Source | 10,754,000Source | 5,024,000Source | 11,312,000Source | 2,901,000Source | 15,301,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 26,000Source | — | 29,000Source | — | 29,000Source | — | 48,000Source | — | 32,000Source | 30,000Source | 33,000Source | 152,000Source |
| Inventory, NetUSD | 0Source | — | 640,000Source | — | — | — | 408,000Source | — | — | 0Source | 297,000Source | — |
| Assets, CurrentUSD | 2,100,000Source | — | 4,783,000Source | — | 3,226,000Source | — | 7,283,000Source | — | 6,627,000Source | 12,131,000Source | 3,936,000Source | 17,048,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 913,000Source | — | 940,000Source | — | 511,000Source | — | 640,000Source | — | 557,000Source | 789,000Source | 705,000Source | 889,000Source |
| Operating Lease, Right-of-Use AssetUSD | 978,000Source | — | 1,086,000Source | — | 287,000Source | — | 1,194,000Source | — | 407,000Source | 867,000Source | 1,299,000Source | 1,705,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 3,480,000Source | — | 3,074,000Source | — | 6,193,000Source | — | 2,808,000Source | — | 8,485,000Source | 4,158,000Source | 2,748,000Source | 4,984,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 17,000Source | — | 15,000Source | — | 3,000Source | — | 14,000Source | — | 3,000Source | 2,000Source | 10,000Source | 9,000Source |
| Retained Earnings (Accumulated Deficit)USD | -349,009,000Source | — | -345,562,000Source | — | -357,338,000Source | — | -343,013,000Source | — | -356,000,000Source | -342,157,000Source | -339,669,000Source | -324,998,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | 1,000Source | — | — | — | — | — | — | — | 0Source | 2,000Source |
| Stockholders' Equity Attributable to ParentUSD | 364,000Source | — | 3,680,000Source | — | -2,346,000Source | — | 6,662,000Source | — | -1,099,000Source | 10,492,000Source | 3,601,000Source | 15,329,000Source |
| Additional Paid in Capital, Common StockUSD | 349,357,000Source | — | 349,227,000Source | — | 354,989,000Source | — | 349,662,000Source | — | 354,898,000Source | 352,648,000Source | 343,261,000Source | 340,317,000Source |
| Liabilities and EquityUSD | 3,844,000Source | — | 6,754,000Source | — | 3,847,000Source | — | 9,470,000Source | — | 7,386,000Source | 14,650,000Source | 6,349,000Source | 20,313,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,937,000Source | — | 2,414,000Source | — | 1,893,000Source | — | 2,033,000Source | — | 2,785,000Source | 3,737,000Source | 1,860,000Source | 3,671,000Source |
| Operating Lease, Liability, CurrentUSD | 517,000Source | — | 513,000Source | — | 316,000Source | — | 510,000Source | — | 447,000Source | 521,000Source | 506,000Source | 492,000Source |
| Accounts Payable, CurrentUSD | 930,000Source | — | 419,000Source | — | 621,000Source | — | 1,119,000Source | — | 1,021,000Source | 1,644,000Source | 627,000Source | 331,000Source |
| Operating Lease, Liability, NoncurrentUSD | 543,000Source | — | 660,000Source | — | 0Source | — | 775,000Source | — | 0Source | 421,000Source | 888,000Source | 1,313,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 1,015,000Source | — | 879,000Source | — | 738,000Source | — | 404,000Source | — | 981,000Source | 1,226,000Source | 727,000Source | 2,848,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q1 2027 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -3,447,000Source | -3,604,000Source | -2,549,000Source | -1,338,000Source | -2,843,000Source | -3,344,000Source | -13,843,000Source | -2,488,000Source | -14,671,000Source | -17,259,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | 40,000Source | 61,000Source | 70,000Source | 215,000Source | 266,000Source | 280,000Source | 293,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | -3,000Source | 2,000Source | 15,000Source | 2,000Source | -3,000Source | -119,000Source | 152,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | 111,000Source | 0Source | 501,000Source | 297,000Source | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | -400,000Source | -971,000Source | 492,000Source | -623,000Source | 1,017,000Source | 296,000Source | -148,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | -3,213,000Source | -3,940,000Source | -2,983,000Source | -10,827,000Source | -9,461,000Source | -14,653,000Source | -12,408,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | -23,000Source | 0Source | 20,000Source | 94,000Source | 9,025,000Source | 816,000Source | -966,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | 23,000Source | 0Source | 0Source | 0Source | 13,000Source | 42,000Source | 396,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | -118,000Source | 1,683,000Source | 6,249,000Source | 4,445,000Source | 8,847,000Source | 1,437,000Source | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | -3,354,000Source | -2,257,000Source | 3,286,000Source | -6,288,000Source | 8,411,000Source | -12,400,000Source | -13,374,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | 4,000Source | 4,000Source | 0Source | 12,000Source | 10,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 130,000Source | 157,000Source | 155,000Source | 91,000Source | 78,000Source | 156,000Source | 303,000Source | 532,000Source | 1,508,000Source | 2,377,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 200,000Source | 300,000Source | 0.3Source | 211,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | 0Source | 0Source | 0Source | — | — | 0Source | 94,000Source | 0Source | 12,000Source | 29,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -9,000Source |
| Gain (Loss) on Disposition of BusinessUSD | — | — | — | — | — | — | — | — | 0Source | 10,000,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | 0Source | 10,000,000Source | 0Source | -9,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 3,000Source | 0Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source |
| InterestExpenseNonoperatingUSD | — | — | 5,000Source | 0Source | 0Source | 4,000Source | 4,000Source | 0Source | 12,000Source | 10,000Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | 0Source | 798,000Source | — | — |
| Investment Income, InterestUSD | — | — | 26,000Source | 76,000Source | 59,000Source | 28,000Source | 76,000Source | 44,000Source | 267,000Source | 140,000Source | 405,000Source | 454,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,447,000Source | -3,604,000Source | -2,549,000Source | -1,338,000Source | -2,843,000Source | -3,344,000Source | -13,843,000Source | -2,488,000Source | -14,671,000Source | -17,259,000Source |
| Nonoperating Income (Expense)USD | — | — | 21,000Source | 76,000Source | 59,000Source | 1,424,000Source | 72,000Source | 44,000Source | -2,354,000Source | 10,130,000Source | 417,000Source | 474,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 499,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | 0Source | 1,811,000Source | 6,249,000Source | 4,808,000Source | 8,847,000Source | 1,437,000Source | 0Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q1 2027 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 24,000Source | 5,000Source | 30,000Source | 18,000Source | 37,000Source | 39,000Source | 131,000Source | 144,000Source | 109,000Source | 370,000Source |
| Cost of RevenueUSD | — | — | 2,000Source | 0Source | 1,000Source | — | — | 2,000Source | 0Source | 5,000Source | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 1,710,000Source | 2,251,000Source | 1,653,000Source | 1,645,000Source | 1,951,000Source | 2,021,000Source | 7,429,000Source | 7,730,000Source | 9,697,000Source | 9,216,000Source |
| Operating Income (Loss)USD | — | — | -3,468,000Source | -3,680,000Source | -2,608,000Source | -2,759,000Source | -2,915,000Source | -3,386,000Source | -11,487,000Source | -12,616,000Source | -15,086,000Source | -17,731,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -13,841,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 3,000Source | 0Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,447,000Source | -3,604,000Source | -2,549,000Source | -1,338,000Source | -2,843,000Source | -3,344,000Source | -13,843,000Source | -2,488,000Source | -14,671,000Source | -17,259,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -2.28Source | -0.4Source | -1.68Source | -0.25Source | -1.14Source | -2.74Source | -5.35Source | -1.7Source | -1.6Source | -1.98Source |
| Earnings Per Share, DilutedUSD per share | — | — | -2.28Source | -0.4Source | -1.68Source | -0.25Source | -1.14Source | -2.74Source | -5.35Source | -1.7Source | -1.6Source | -1.98Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 1,504,713Source | 9,115,455Source | 1,499,544Source | 5,239,462Source | 2,503,697Source | 1,221,974Source | 2,588,327Source | 1,463,609Source | 9,144,922Source | 8,713,032Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,504,713Source | 9,115,455Source | 1,499,544Source | 5,239,462Source | 2,503,697Source | 1,221,974Source | 2,588,327Source | 1,463,609Source | 9,144,922Source | 8,713,032Source |
| Interest Expense (non-operating)USD | — | — | 5,000Source | 0Source | 0Source | 4,000Source | 4,000Source | 0Source | 12,000Source | 10,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 3,492,000Source | 3,685,000Source | 2,638,000Source | 2,777,000Source | 2,952,000Source | 3,425,000Source | 11,618,000Source | 12,760,000Source | 15,195,000Source | 18,101,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -13,841,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | 26,000Source | 76,000Source | 59,000Source | 28,000Source | 76,000Source | 44,000Source | 267,000Source | 140,000Source | 405,000Source | 454,000Source |
| Nonoperating Income (Expense)USD | — | — | 21,000Source | 76,000Source | 59,000Source | 1,424,000Source | 72,000Source | 44,000Source | -2,354,000Source | 10,130,000Source | 417,000Source | 474,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 499,000Source |
| Research and Development ExpenseUSD | — | — | 1,780,000Source | 1,434,000Source | 984,000Source | 1,132,000Source | 1,001,000Source | 1,402,000Source | 4,189,000Source | 5,025,000Source | 5,498,000Source | 8,885,000Source |
Offerings
Registration 333-297892
Registration 333-294716
- Gross proceeds
- 3997655.06
- Net proceeds
- 3697655.05
- Deal price
- 1.14
- Shares
- 3506715
- Offering price
- $1.14
- Ticker
- VIVS
Underwriters: Joseph Gunnar & Co., LLC
Filing attachments
vivs-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 vivs-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 VivoSim Provides Financial and Listing Compliance Update San Diego, CA - August 6, 2026 - VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that on August 4, 2026, we received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that the Company has regained com…
Read attachment ↗d134319dex41.htm · 8-K · 2026-07-17
EX-4.1 2 d134319dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT T…
Read attachment ↗d134319dex42.htm · 8-K · 2026-07-17
EX-4.2 3 d134319dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT T…
Read attachment ↗d134319dex43.htm · 8-K · 2026-07-17
EX-4.3 4 d134319dex43.htm EX-4.3 EX-4.3 Exhibit 4.3 AMENDMENT TO COMMON STOCK PURCHASE WARRANT This AMENDMENT TO COMMON STOCK PURCHASE WARRANT (this “Amendment”) is entered into as of July 16, 2026, by and between VivoSim Labs, Inc., a Delaware corporation (the “Company”), and Armistice Capital Master Fund Ltd. (the “Holder”). WHEREAS, the Company issued to the Holder those certain Common Stock Purchase Warrants (the “Original Warrants”) on May 13, 2024; WHEREAS, the Original Warrants …
Read attachment ↗d134319dex991.htm · 8-K · 2026-07-17
EX-99.1 7 d134319dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) - VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that it has entered into a securities purcha…
Read attachment ↗vivs-ex4_5.htm · 10-K · 2026-07-14
Exhibit 4.5 DESCRIPTION OF VIVOSIM LABS, INC.’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the common stock, par value $0.001 per share, of VivoSim Labs, Inc. (“us,” “our,” “we,” or the “Company”), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), summarizes certain information regarding the common stock in our certificate of incor…
Read attachment ↗